XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)

Royalty and Commercial Payment Purchase Agreements - Bioasis (Details) $ in Thousands			3 Months Ended	9 Months Ended		12 Months Ended
	Nov. 02, 2020 USD ($)	Feb. 25, 2019 USD ($) agreement	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Agreements
Payments related to purchase of royalty rights and other commercial payment rights					$ 20,500
Long-term royalty and commercial payment receivables			$ 66,049	$ 66,049		$ 69,075
Contingent consideration under RPAs and CPPAs			75	75		8,075
Impairment of long-term royalty receivable				0		0
Bioasis \| Royalty Purchase Agreement
Agreements
Percentage of option to purchase royalty right on future license agreements		1.00%
Number of future license agreements under optional purchase right \| agreement		2
Obligation upon exercise of options per licensed product, second agreement		$ 300
Obligation upon exercise of options per licensed product, third agreement		400
Payments related to purchase of royalty rights and other commercial payment rights		300
Long-term royalty and commercial payment receivables		400
Contingent consideration under RPAs and CPPAs		100	100	100
Changes in estimated fair value of contingent consideration				0
Payments of contingent consideration			$ 0	0
Impairment of long-term royalty receivable				0		0
Bioasis \| Royalty Purchase Agreement \| Maximum
Agreements
Potential future cash payments		$ 200
Bioasis \| Second Royalty Purchase Agreement
Agreements
Payments related to purchase of royalty rights and other commercial payment rights	$ 1,200
Long-term royalty and commercial payment receivables	$ 1,200
Impairment of long-term royalty receivable				$ 0		$ 0